|Dr. Maria L. MacCecchini||Founder, CEO, Pres & Director||120k||N/A||1951|
|Mr. Jeffrey B. McGroarty CPA||Chief Financial Officer||N/A||N/A||1969|
|Dr. Jeffrey L. Cummings||Chief Medical Officer & Member of Scientific Advisory Board||N/A||N/A||1950|
|Dr. William C. Mobley||Chief Scientific Advisor & Member of Scientific Advisory Board||N/A||N/A||N/A|
Annovis Bio, Inc., a clinical stage drug platform company, focuses on developing compounds to address neurodegeneration. The company's lead compound is ANVS-401, which is in Phase 2a clinical trials for the treatment of chronic neurodegenerative diseases, such as Down syndrome, Alzheimer's disease (AD), and Parkinson's disease. It is also developing ANVS-301, a compound in Phase 1 clinical trials to increase cognitive capability in later stages of AD and dementia; and ANVS-405, which is in preclinical study for protecting the brain after traumatic brain injury and/or stroke. Annovis Bio, Inc. was formerly known as QR Pharma, Inc. and changed its name to Annovis Bio, Inc. in March 2019. The company was founded in 2008 and is based in Berwyn, Pennsylvania.
Annovis Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.